Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 9/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.36 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.36 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061152 | 0.77 | ALDH1A1 (0.48) | TLR9ALDH1A1HSP90AA1PKMATM | |
| SCHEMBL2222585 | 0.75 | DDAH1 (0.51) | ALDH1A1HSP90AA1PKMNPSR1CCR6 | |
| SCHEMBL229803 | 0.74 | MGLL (0.47) | ALDH1A1HSP90AA1PKMATMNPSR1 | |
| SCHEMBL1934695 | 0.74 | MCL1 (0.46) | ALDH1A1PKMGAAHTTSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28851009 | 0.72 | MCL1 (0.45) | ALDH1A1PKMGAAHTTSMN1; SMN2 | |
| SCHEMBL183052 | 0.70 | ALDH1A1 (0.71) | TLR9ALDH1A1HSP90AA1PKMATM | |
| SCHEMBL29364136 | 0.70 | ALDH1A1 (0.71) | TLR9ALDH1A1HSP90AA1PKMATM | |
| SCHEMBL9240798 | 0.69 | TLR9 (0.64) | TLR9ALDH1A1HSP90AA1PKMATM | |
| Hydrochloric Acid SCHEMBL6753288 | 0.69 | ALDH1A1 (0.69) | TLR9ALDH1A1HSP90AA1PKMATM | |
| SCHEMBL10938557 | 0.69 | ALDH1A1 (0.64) | TLR9ALDH1A1HSP90AA1PKMATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| EP-2290100-B1 | Kits for displacement Sandwich Immuno-PCR | IRIS INT INC (US) | 2014-02-19 | — | — | EP | claimed |
| EP-1704167-B1 | A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-01-12 | — | — | EP | claimed |
| EP-1689846-A2 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES | Immunogen, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| EP-0941738-B1 | Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria | WYETH CORP (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2005037992-A2 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| WO-1998057578-A1 | APPLICATION OF ?13C-13C, 13C-15N, AND 13C-13C-15¿N ISOTOPICALLY ENRICHED PROTEINS AS TISSUE-DIRECTED IMAGE-ENHANCEMENT REAGENTS FOR MAGNETIC RESONANCE IMAGING | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0366770-B1 | LIPOSOMES COUPLED TO HORMONES | VESTAR INC (US) | 1994-02-09 | — | — | EP | claimed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | disclosed |
| US-12624087-B2 | CD155 variant immunomodulatory proteins and uses thereof | ALPINE IMMUNE SCIENCES, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612446-B2 | CTLA-4 variant immunomodulatory proteins and uses thereof | ALPINE IMMUNE SCIENCES, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3349796-B1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | IMMUNOGEN INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4717707-A2 | VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS | Alpine Immune Sciences, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4706777-A2 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | Alpine Immune Sciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-0485471-A1 | NATURAL HUMAN ANTI-GAMMA INTERFERON ANTIBODIES DETECTED AND PURIFIED BY SYNTHETIC PEPTIDES. | TURANO ADOLFO (IT) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991002005-A1 | NATURAL HUMAN ANTI-GAMMA INTERFERON ANTIBODIES DETECTED AND PURIFIED BY SYNTHETIC PEPTIDES | TURANO ADOLFO (IT) | 1991-02-21 | — | — | WO | disclosed |
| EP-0317804-A2 | HIV peptides and methods for detection of HIV | ABBOTT LABORATORIES (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0275278-A1 | PEPTIDE FRAGMENTS OF ORGAN-SPECIFIC NEOANTIGENS | BIO-RAD LABORATORIES, INC. (US) | 1988-07-27 | — | — | EP | disclosed |
| WO-1988000344-A1 | PEPTIDE FRAGMENTS OF ORGAN-SPECIFIC NEOANTIGENS | BIO-RAD LABORATORIES, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0235391-A2 | Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses | The University of Saskatchewan (CA) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624087-B2 | CD155 variant immunomodulatory proteins and uses thereof | CD2BP2, CD2, LY96 | TLR9 474/4885ALDH1A1 4268/4885HSP90AA1 1193/4885 |
| US-12612446-B2 | CTLA-4 variant immunomodulatory proteins and uses thereof | CD2, CD274, IGSF11 | TLR9 141/4885ALDH1A1 4442/4885HSP90AA1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.